Adamska-Dyniewska H, Chojnowska-Jezierska J, Cybulska B, Grzymisławski M, Hryniewiecki L, Kaliciński A, Kawecka-Jaszcz K, Kleinrok A, Kłos Z J, Kokot F
Instytut Chorób Wewnetrznych WAM w Lodzi.
Pol Arch Med Wewn. 1994 Jul;92(1):54-62.
In 9 clinics 177 patients (68 men and 109 women) aged 23-69 years with primary hypercholesterolemia (TC above 6.5 mmol/L) were treated with lovastatin for 12 weeks. The treatment was started with 20 mg daily. The dose was doubled every 4 weeks, if the total serum cholesterol level did not fall below 5.2 mmol/L. For 4 weeks before treatment with lovastatin all patients received placebo. After the first 4 weeks of therapy the mean TC level decreased significantly (from 8.09 mmol/L to 6.54 mmol/L) by 18.5%. In comparison with the results after placebo (the starting value), after the 8 weeks of the therapy the TC level reduction reached 22.4% and after 12 weeks 23.5%. The mean LDL cholesterol decreased by 26.1%, 30.8% and 32.9% after 4.8 and 12 weeks of lovastatin treatment respectively. An increase in HDL cholesterol by 5.9%, 6.0% and 7.6% and decrease in triglyceride level by 10.7%, 14.9% and 14.0% respectively was also observed. In 6 patients on lovastatin treatment symptoms of acute pancreatitis in 1 case, a cataract in 1 case and aggravation of coronary insufficiency in 4 cases were noticed. These symptoms in the light of our knowledge of the mechanism of action of the drug used and of its side effects described in other trials, may be considered of independent on lovastatin. The treatment was discontinued in 5 cases (because of gastrointestinal intolerance in 2 patients, of aggravation of coronary insufficiency in 2 patients and of pain in the right hypochondrium in 1 patient who himself decided to stop the therapy).(ABSTRACT TRUNCATED AT 250 WORDS)
在9家诊所中，对177例年龄在23至69岁之间的原发性高胆固醇血症（总胆固醇高于6.5 mmol/L）患者（68名男性和109名女性）使用洛伐他汀进行了12周的治疗。治疗起始剂量为每日20 mg。如果总血清胆固醇水平未降至5.2 mmol/L以下，则每4周将剂量加倍。在使用洛伐他汀治疗前4周，所有患者均接受安慰剂治疗。治疗的前4周后，平均总胆固醇水平显著下降（从8.09 mmol/L降至6.54 mmol/L），降幅为18.5%。与安慰剂治疗后的结果（起始值）相比，治疗8周后总胆固醇水平降低了22.4%，12周后降低了23.5%。洛伐他汀治疗4周、8周和12周后，平均低密度脂蛋白胆固醇分别下降了26.1%、30.8%和32.9%。还观察到高密度脂蛋白胆固醇分别升高了5.9%、6.0%和7.6%，甘油三酯水平分别下降了10.7%、14.9%和14.0%。在6例接受洛伐他汀治疗的患者中，注意到1例出现急性胰腺炎症状，1例出现白内障，4例出现冠状动脉供血不足加重。根据我们对所用药物作用机制及其在其他试验中描述的副作用的了解，这些症状可能被认为与洛伐他汀无关。5例患者停止了治疗（2例因胃肠道不耐受，2例因冠状动脉供血不足加重，1例因右季肋部疼痛而自行决定停止治疗）。（摘要截断于250字）
